{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:27:05Z","timestamp":1761568025910,"version":"build-2065373602"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:p>Angiolymphoid hyperplasia with eosinophilia (ALHE) is a benign vasoproliferative condition of unclear aetiology. Management of AHLE is challenging because of a lack of effective treatment and a high tendency for recurrence. We present a case of ALHE with concomitant atopic dermatitis that was successfully treated with dupilumab.<\/jats:p>","DOI":"10.1093\/ced\/llaf289","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T07:45:16Z","timestamp":1750491916000},"page":"2288-2290","source":"Crossref","is-referenced-by-count":1,"title":["A case of angiolymphoid hyperplasia with eosinophilia successfully treated with dupilumab"],"prefix":"10.1093","volume":"50","author":[{"given":"Howard Jie","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Monash Health , Clayton, VIC ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Monash Health , Clayton, VIC ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Monash Health , Clayton, VIC ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senhong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Monash Health , Clayton, VIC ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis\u00a0Yi\u00a0Xing","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Monash Health , Clayton, VIC ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2025102707122087300_llaf289-B1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2015.10.011","article-title":"Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): a systematic review","volume":"74","author":"Adler","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025102707122087300_llaf289-B2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/ced.14940","article-title":"Percutaneous ethanol sclerotherapy is a promising treatment for recalcitrant angiolymphoid hyperplasia with eosinophilia","volume":"47","author":"Galili","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2025102707122087300_llaf289-B3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jamadermatol.2022.1969","article-title":"Use of dupilumab and eosinophil targeted therapy in treating angiolymphoid hyperplasia with eosinophilia","volume":"158","author":"Franke","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025102707122087300_llaf289-B4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1365-2133.2004.06239.x","article-title":"Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab)","volume":"151","author":"Braun-Falco","year":"2004","journal-title":"Br J Dermatol"},{"key":"2025102707122087300_llaf289-B5","doi-asserted-by":"crossref","first-page":"e1072","DOI":"10.1111\/jdv.19116","article-title":"Angiolymphoid hyperplasia with eosinophilia infiltrated by GATA3+ Th2 cells responding to dupilumab","volume":"37","author":"Seidl","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf289\/63546619\/llaf289.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2288\/63546619\/llaf289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/11\/2288\/63546619\/llaf289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:12:31Z","timestamp":1761563551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/11\/2288\/8171616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":5,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf289","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,23]]}}}